secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076612
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium Therapeutics FY2025 cash $411.6M; Phase 3 MDD trial fully enrolled, topline late Q2 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $411.6M as of Dec 31, 2025, up from $273.7M in 2024; expected to fund operations into 2028.
- Phase 3 MDD trial Emerge fully enrolled (149 patients); topline data anticipated late 2Q 2026.
- Phase 3 GAD trial Voyage ~80% enrolled, no sample size increase needed; topline early 3Q 2026.
- Phase 3 GAD trial Panorama enrollment on track; topline 2H 2026. Sample size re-estimation update on April 22 Investor Day.
- Completed $259M equity financing in Q4 2025; appointed new CFO, CCO, and board member Roger Adsett.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/0001193125-26-076612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526076612/dftx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer